FDA's off-label guidance may be up for review

Share this article:
The Obama administration will review and may change an FDA guidance on off-label marketing that was approved in the waning days of the Bush administration, according to McClatchy Newspapers. The news group quoted Sen. Chuck Grassley (R-IA), a frequent FDA critic, as saying that a “legislative fix may be in order.” Grassley had said he had serious concerns about a guidance that would deem as appropriate something that “FDA once considered evidence of unlawful marketing.”

The new policy was disclosed in a Jan. 12 final guidance for industry that skipped the customary “draft” document stage for the gathering of comments. The document was issued not by the FDA's drug or medical device centers which would normally handle such matters, but by the politicized Office of the Commissioner.
Previous agency policy had for many years disfavored dissemination of unapproved use info by drug companies, but the agency was forced by congressional and court intervention to tolerate it under provisions that expired in 2006. 
Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"